Hypothesis: Connexin and pannexin channel dysfunction drives dopaminergic neurodegeneration through impaired cellular communication, calcium dysregulation, and neuroinflammation.
Primary Objective: Validate that connexin hemichannel dysfunction is a disease-modifying mechanism in PD.
Model: iPSC-derived dopaminergic neurons from:
- Healthy controls (n=3 lines)
- PD patients with SNCA triplication (n=2 lines)
- PD patients with LRRK2 G2019S (n=2 lines)
Endpoints:
- Cx36 gap junction coupling ( dye transfer assay)
- Cell viability (MTS assay) under basal and stress conditions
- Calcium dynamics (Fluo-4 AM imaging)
- α-Synuclein aggregation (pSer129 immunostaining)
Interventions:
- Vehicle control
- α-Synuclein pre-formed fibrils (10 μg/mL, 24h)
- Carbenoxolone (100 μM, Cx hemichannel blocker)
- Gap26 (100 μM, Cx43 specific blocker)
Model: Primary rat astrocytes + human iPSC neurons in transwell system
Endpoints:
- Cx43 expression and localization (confocal microscopy)
- Lactate transport (Seahorse metabolic assay)
- K+ buffering capacity (ion-selective microelectrodes)
- Neuronal survival under metabolic stress
Design: C57BL/6 mice, 8 weeks old, n=12/group
| Group |
Treatment |
Dose |
Duration |
| 1 |
Vehicle |
- |
4 weeks |
| 2 |
MPTP |
30 mg/kg |
4 weeks |
| 3 |
MPTP + Carbenoxolone |
50 mg/kg |
4 weeks |
| 4 |
MPTP + Gap26 |
3 mg/kg |
4 weeks |
| 5 |
Probenecid |
50 mg/kg |
4 weeks |
Endpoints:
- Behavioral: Rotarod, cylinder test, gait analysis
- Histological: TH+ neuron count in SNc, striatal dopamine
- Molecular: Cx43, PANX1 expression (Western blot)
- Inflammation: Iba1+ microglial density, IL-1β levels
Design: C57BL/6 mice, unilateral striatal PFF injection, n=10/group
Endpoints:
- pSer129 α-synuclein pathology (15, 30, 60 days)
- Cx43 hemichannel activity (ethidium bromide uptake)
- Optogenetic assessment of circuit function
Cohort:
- Early PD (n=50, H&Y 1-2)
- Advanced PD (n=50, H&Y 3-4)
- Healthy controls (n=30)
Biomarkers:
- Extracellular ATP (luminex assay)
- IL-1β, IL-18 (ELISA)
- Neurofilament light chain (NfL)
- α-Synuclein seeding (RT-QuIC)
Correlations:
- UPDRS motor scores
- Disease duration
- MoCA cognitive scores
For Phase 2 (animal study):
- α = 0.05, power = 0.80
- Expected effect size (Cohen's d) = 1.2
- n = 10 per group provides adequate power
| Endpoint |
Analysis |
| TH+ neuron count |
One-way ANOVA + Tukey post-hoc |
| Behavioral scores |
Repeated measures ANOVA |
| Biomarker levels |
Linear mixed effects model |
| Correlation analysis |
Pearson/Spearman as appropriate |
¶ Risks and Mitigations
| Risk |
Mitigation |
| Limited BBB penetration of blockers |
Use multiple compounds with different properties |
| Species differences |
Validate in human iPSC models |
| Off-target effects |
Use isoform-selective compounds where available |
| Biomarker variability |
Standardized collection protocols, multi-analyte panels |
- Confirm α-Synuclein-induced gap junction dysfunction in human neurons
- Demonstrate therapeutic efficacy of hemichannel blockers in animal models
- Validate extracellular ATP as PD biomarker
- Establish Cx43/PANX1 as druggable targets
| Phase |
Duration |
Estimated Cost |
| Phase 1 (in vitro) |
6 months |
$150,000 |
| Phase 2 (animal) |
12 months |
$400,000 |
| Phase 3 (clinical) |
18 months |
$350,000 |
| Total |
36 months |
$900,000 |
Month: 1---6---12---18---24---30---36
| | | | | | |
P1: [=====]